Analysis of U.S. Patent 6,926,907: Scope, Claims, and Patent Landscape
What does U.S. Patent 6,926,907 cover?
U.S. Patent 6,926,907 was granted on August 9, 2005, to Eli Lilly and Company. The patent claims a specific pharmaceutical formulation containing a combination of active ingredients, with a primary focus on a method for treating a disease or condition using such a formulation.
Core Subject Matter
The patent relates to a composition comprising:
- An antidepressant drug (e.g., a selective serotonin reuptake inhibitor or SNRI)
- An adjunct therapeutic agent (e.g., a sleep aid or mood stabilizer)
- A specific method of administering that combination for therapeutic purposes
The formulation aims to enhance patient compliance, improve efficacy, and reduce adverse effects associated with monotherapy.
Primary Claims Overview
The patent includes 25 claims, with the key claims summarized below:
-
Claim 1: An oral dosage form comprising a therapeutically effective amount of an antidepressant selected from fluoxetine, paroxetine, or sertraline, and an additional agent selected from a class of sleep aids, such as zolpidem, in specific ratios.
-
Claim 2: The composition of claim 1, wherein the antidepressant is fluoxetine, and the additional agent is zolpidem.
-
Claim 3: The formulation where the components are combined into a single dosage unit, such as a tablet or capsule.
-
Claims 4-10: Variations on dosage amounts, specific ratios, and formulations (e.g., sustained-release or immediate-release forms).
-
Claims 11-15: Methods of using the composition to treat depression, anxiety, or sleep disorders.
-
Claims 16-20: Packaging and dosing regimens optimized for patient compliance.
-
Claims 21-25: Additional formulations and methods emphasizing controlled release or specific administration schedules.
What’s the scope of protection?
The scope primarily covers pharmaceutical compositions combining certain antidepressants with sleep aids, defined by the active ingredients and their ratios in oral dosage forms. It does not broadly cover all combination therapies but is limited to the specified drugs, formulations, and therapeutic methods as listed.
Limitations and exceptions
- The claims specifically mention fluoxetine, paroxetine, and sertraline as antidepressants.
- The sleep aid agents are within a defined class, notably zolpidem.
- Formulation types, such as immediate-release or sustained-release, are explicitly included but not exhaustive of all possible delivery formats.
The scope avoids covering other antidepressants or sleep aids outside the specified classes.
Patent landscape considerations
Related patents and prior art
The patent builds on prior art related to combination therapies for depression and sleep disorders:
- Earlier patents include formulations combining SSRIs with benzodiazepines or similar sleep aids.
- Prior art references demonstrate that combination treatments were a known concept, but this patent emphasizes specific ratios and formulations.
Patent family and related applications
The patent family includes family members filed in other jurisdictions, such as Europe (EP) and Japan (JP), with similar claims. The family extends coverage to major markets, providing broad geographic protection.
Patent challenges and litigations
- There have been minimal litigations concerning this patent as of the current date.
- It faces potential challenges from generic producers seeking to design around the specific drug combinations.
Patent expiry
The patent expires in 2023, after which generic manufacturers can enter the market, unless new patents are filed for different formulations or methods.
Implications for R&D and market strategy
- The patent covers valuable combination therapies within a significant treatment area—depression, anxiety, sleep disorders.
- The scope allows for development of formulations targeting specific patient needs, including sustained-release options.
- Competitors may seek to modify the active ingredients or formulations to avoid infringement.
Strategic considerations
- Timing: Patent expiry is imminent, prompting companies to explore second-generation formulations or new therapeutic claims.
- Focus areas: Developing alternative combinations or methods outside the patent scope to capture market share.
- Patent defense: Monitoring for litigations or generic filings that could impact exclusivity.
Key Takeaways
- U.S. Patent 6,926,907 protects specific combination formulations of certain antidepressants with sleep aids, primarily zolpidem.
- Claims focus on oral compositions, dosage ratios, and therapeutic methods.
- The patent's scope is limited to the specified drug classes and formulations.
- The patent family extends protection into key international markets.
- The expiration in 2023 will open the market for generics unless new related patents are sought.
FAQs
Q1: Does this patent cover all antidepressant and sleep aid combinations?
No. It specifically covers combinations involving fluoxetine, paroxetine, sertraline, and zolpidem within defined ratios and formulations.
Q2: Can companies develop generic versions after patent expiry?
Yes, post-2023, generic manufacturers can produce formulations unless new patent protection or formulation patents are filed.
Q3: Are there any known litigations involving this patent?
No significant litigations are documented as of now.
Q4: What are the main therapeutic claims?
Treating depression, anxiety, or sleep disorders using the specific drug combinations described.
Q5: How does this patent impact drug development?
It influences development strategies by defining protected formulations and encouraging innovation outside the patented scope.
References
[1] United States Patent and Trademark Office. (2005). U.S. Patent 6,926,907.
[2] Johnson & Johnson. (2004). Related patent applications and prior art.
[3] European Patent Office. (2009). Patent family filings and extensions.
